(4-(m-chlorophenylcarbamoyloxy)-2-butynyl)trimethylammonium chloride has been researched along with Sicca Syndrome in 1 studies
(4-(m-Chlorophenylcarbamoyloxy)-2-butynyl)trimethylammonium Chloride: A drug that selectively activates certain subclasses of muscarinic receptors and also activates postganglionic nicotinic receptors. It is commonly used experimentally to distinguish muscarinic receptor subtypes.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The dose-response curves for SNI-2011 were approximately parallel to curves for pilocarpine but the potency of SNI-2011 was about 25-fold lower than that of pilocarpine." | 1.29 | Sialogogic activities of SNI-2011 compared with those of pilocarpine and McN-A-343 in rat salivary glands: identification of a potential therapeutic agent for treatment of Sjörgen's syndrome. ( Iwabuchi, Y; Masuhara, T, 1994) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Iwabuchi, Y | 1 |
| Masuhara, T | 1 |
1 other study available for (4-(m-chlorophenylcarbamoyloxy)-2-butynyl)trimethylammonium chloride and Sicca Syndrome
| Article | Year |
|---|---|
Sialogogic activities of SNI-2011 compared with those of pilocarpine and McN-A-343 in rat salivary glands: identification of a potential therapeutic agent for treatment of Sjörgen's syndrome.
Topics: (4-(m-Chlorophenylcarbamoyloxy)-2-butynyl)trimethylammonium Chloride; Adrenergic Antagonists; Animal | 1994 |